吡格列酮对2型糖尿病患者骨转换生化指标的影响  

The effects of pioglitazone on biochemical markers of bone turnover in patients with type 2 diabetes

作　　者：谢超[1] 侯文芳[1] 洪天配[1] 肖文华[1] 王艳荣[1] 王海宁[1] 高洪伟[1] 

机构地区：[1]北京大学第三医院内分泌科,100191

出　　处：《中国糖尿病杂志》2010年第3期195-197,共3页Chinese Journal of Diabetes

基　　金：国家973计划资助项目(2006CB503900);国家自然科学基金资助项目(30771032;30700879);国家863计划资助项目(2006AA02A112)

摘　　要：目的观察吡格列酮对2型糖尿病患者骨转换生化指标的影响。方法比较70例2型糖尿病患者加用吡格列酮治疗12周前后血清Ⅰ型原胶原N末端前肽(PINP)、总碱性磷酸酶(T-ALP)、骨钙素(OC)、Ⅰ型胶原交联C末端肽(CTX)等骨转化指标的变化。结果吡格列酮治疗12周后,2型糖尿病患者血清PINP和T-ALP水平较治疗前明显降低(P<0.01),并且这种下降作用主要来源于女性亚组的贡献。OC和CTX在治疗前后无明显变化。结论吡格列酮可抑制骨形成,而对骨吸收则可能无明显影响,提示吡格列酮对2型糖尿病患者骨转换的影响主要是抑制骨形成。Objective To investigate the effects of pioglitazone on biochemical markers of bone turnover in patients with type 2 diabetes. Methods Seventy patients with type 2 diabetes were enrolled in this study. Pioglitazone was added into blood glucose control regimens for 12 weeks. The biochemical markers of bone turnover, including procollagen type Ⅰ amino-terminal propeptide （PINP）, total alkaline phosphatase （T-ALP）, osteoealcin （OC） and cross linked C-telopeptide of collage type Ⅰ （CTX）, were evaluated at baseline and 12 weeks after pioglitazone treatment. Results After 12 weeks of pioglitazone treatment, serum levels of PINP and total T-ALP were significantly decreased （P〈0. 01） in female patients, but not in male patients. The levels of OC and CTX were unchanged in all the patients. Conclusions Pioglitazone treatment for 12 weeks inhibits bone formation but does not significantly alter bone resorption. The results indicate that abnormal bone turnover may be mainly due to impaired bone formation in pioglitazone-treated patients with type 2 diabetes.

关 键 词：吡格列酮 糖尿病 2型 骨转换 

分 类 号：R587.1[医药卫生—内分泌]